Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US13463J1016
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00L2CHQ80
CAMP
CAMP4 Therapeutics Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
CAMP4 Therapeutics Corp
ISIN
US13463J1016
TICKER
CAMP
MIC
XNAS
REUTERS
CAMP.OQ
BLOOMBERG
CAMP US
Fr., 19.06.2026       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of ge...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 14.05.2026       Camp4 Therapeutics
US13463J1016

CMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Camp4 Therapeutics
US13463J1016

Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026 ...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       Camp4 Therapeutics
US13463J1016

Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 06.03.2026       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Camp4 Therapeutics
US13463J1016

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 16.01.2026       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 18.12.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Camp4 Therapeutics
US13463J1016

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 14.11.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 01.10.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.09.2025       Camp4 Therapeutics
US13463J1016

Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 14.08.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases,...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 16.05.2025       Camp4 Therapeutics
US13463J1016

Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, t...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 27.03.2025       Camp4 Therapeutics
US13463J1016

– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 06.02.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President &...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 07.01.2025       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today provided corporate updates and key objectives for 2025....
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 02.12.2024       Camp4 Therapeutics
US13463J1016

CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced that...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 21.11.2024       Camp4 Therapeutics
US13463J1016

- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M...
Zur Nachricht
Camp4 Therapeutics
Charts & Research Termsheets Terminal
Permalink